Filtered By:
Source: Clinical Cancer Research
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 104 results found since Jan 2013.
Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer.
Conclusion: Defective cyclin B1 induction by T-DM1 mediates acquired resistance in HER2 positive breast cancer cells. These results support the testing of cyclin B1 induction upon T-DM1 treatment as a pharmacodynamic predictor in HER2 positive breast cancer.
PMID: 28821558 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - August 18, 2017 Category: Cancer & Oncology Authors: Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpi O, García-Alonso S, Menéndez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martinez-Garcia M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, P Tags: Clin Cancer Res Source Type: research
Overcoming acquired resistance to AZD9291, a third generation EGFR inhibitor, through modulation of MEK/ERK-dependent Bim and Mcl-1 degradation.
Conclusions: <p>Modulation of MEK/ERK-dependent Bim and Mcl-1 degradation critically mediates sensitivity and resistance of EGFR-mutant NSCLC cells to AZD9291 and hence is an effective strategy to overcome acquired resistance to AZD9291.
PMID: 28765329 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - August 1, 2017 Category: Cancer & Oncology Authors: Shi P, Oh YT, Deng L, Zhang G, Qian G, Zhang S, Ren H, Wu G, Legendre B, Anderson E, Ramalingam SS, Owonikoko TK, Chen M, Sun SY Tags: Clin Cancer Res Source Type: research
Association of FGFR1 with ER αmaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer.
Conclusions: These data suggest the ERα pathway remains active in estrogen-deprived ER+/FGFR1-amplified breast cancers. Therefore, these tumors are endocrine resistant and should be candidates for treatment with combinations of ER and FGFR antagonists.
PMID: 28751448 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - July 27, 2017 Category: Cancer & Oncology Authors: Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL Tags: Clin Cancer Res Source Type: research
BRAF inhibitors amplify the pro-apoptotic activity of MEK inhibitors by inducing ER stress in NRAS-mutant melanoma.
Conclusions: <p>The data presented herein encourage further advanced in vivo and clinical studies to evaluate MEKi in combination with ER stress inducing BRAFi as a strategy to treat rapidly progressing NRAS-mutant melanoma.
PMID: 28724666 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - July 19, 2017 Category: Cancer & Oncology Authors: Niessner H, Sinnberg T, Kosnopfel C, Smalley KSM, Beck D, Praetorius C, Mai M, Beissert S, Kulms D, Schaller M, Garbe C, Flaherty KT, Westphal D, Wanke I, Meier F Tags: Clin Cancer Res Source Type: research
Expression and Therapeutic Potential of SOX9 in Chordoma.
Conclusions: <p>Our results demonstrate that SOX9 plays a crucial role in chordoma. Targeting SOX9 provides a new rationale for treatment of chordoma.
PMID: 28606919 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - June 12, 2017 Category: Cancer & Oncology Authors: Chen H, Garbutt C, Spentzos D, Choy E, Hornicek FJ, Duan Z Tags: Clin Cancer Res Source Type: research
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.
Conclusion: HER2 reactivation through acquisition of the HER2L755S mutation was identified as a mechanism of acquired resistance to L-containing HER2-targeted therapy in preclinical HER2-amplified breast cancer models, which can be overcome by irreversible HER1/2 inhibitors.
PMID: 28487443 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - May 9, 2017 Category: Cancer & Oncology Authors: Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang NJ, Ng CKY, Chen E, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness Tags: Clin Cancer Res Source Type: research
Ribonucleotide reductase large subunit (RRM1) as a novel therapeutic target in multiple myeloma.
Conclusions: Our results therefore demonstrate that RRM1 is a novel therapeutic target in MM in preclinical setting, and provide the basis for clinical evaluation of RRM1 inhibitor, alone or in combination with DNA damaging agents, to improve patient outcome in MM.
PMID: 28442502 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - April 25, 2017 Category: Cancer & Oncology Authors: Sagawa M, Ohguchi H, Harada T, Samur MK, Tai YT, Munshi NC, Kizaki M, Hideshima T, Anderson KC Tags: Clin Cancer Res Source Type: research
Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma.
CONCLUSIONS: The present study identifies a novel signaling involving SYK/c-MYC/MALAT1 as a promising therapeutic target for the treatment of EWS.
PMID: 28336564 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 23, 2017 Category: Cancer & Oncology Authors: Sun H, Lin DC, Cao Q, Pang B, Gae DD, Lee VK, Lim HJ, Doan N, Said JW, Gery S, Chow M, Mayakonda A, Forscher C, Tyner JW, Koeffler HP Tags: Clin Cancer Res Source Type: research
The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.
CONCLUSIONS: Overall, these data demonstrate that prexasertib is a specific inhibitor of CHK1 in neuroblastoma and leads to DNA damage and cell death in preclinical models of this devastating pediatric malignancy.
PMID: 28270495 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 6, 2017 Category: Cancer & Oncology Authors: Lowery CD, VanWye AB, Dowless M, Blosser W, Falcon BL, Stewart J, Stephens J, Beckmann RP, Bence Lin A, Stancato LF Tags: Clin Cancer Res Source Type: research
Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.
CONCLUSIONS: Our preclinical studies provide the framework for clinical evaluation of USP1 inhibitors, alone or in combination, as a potential novel MM therapy.
PMID: 28270494 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 6, 2017 Category: Cancer & Oncology Authors: Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, Chauhan D, Anderson KC Tags: Clin Cancer Res Source Type: research
Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma.
CONCLUSIONS: We identified a new MPM molecular subgroup that shares common genetic and transcriptomic characteristics. Our results made it possible to highlight a greater sensitivity to an anticancer compound for this MPM subgroup and to identify a specific potential biomarker.
PMID: 28003305 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - December 20, 2016 Category: Cancer & Oncology Authors: Tranchant R, Quetel L, Tallet A, Meiller C, Renier A, de Koning L, de Reyniès A, Le Pimpec Barthes F, Zucman-Rossi J, Jaurand MC, Jean D Tags: Clin Cancer Res Source Type: research
AMPK-ULK1-mediated autophagy confers resistance to BET inhibitor JQ1 in acute myeloid leukemia stem cells.
CONCLUSIONS: These findings revealed that prosurvival autophagy was one of the mechanisms involved in the resistance AML LSCs to JQ1. Targeting the AMPK/ULK1 pathway or inhibition of autophagy could be an effective therapeutic strategy for combating resistance to BET inhibitors in AML and other types of cancer.
PMID: 27864418 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - November 17, 2016 Category: Cancer & Oncology Authors: Jang JE, Eom JI, Jeung HK, Cheong JW, Lee JY, Kim JS, Min YH Tags: Clin Cancer Res Source Type: research
Biased Expression of the FOXP3 Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance.
CONCLUSIONS: (i) Biased expression of the FOXP3Δ3 isoform in bladder cancer inversely correlates with overall survival, (ii) FOXP3Δ3 induces a unique gene program that mediates cancer differentiation, and (iii) FOXP3Δ3 may augment chemotherapy resistance. Clin Cancer Res; 22(21); 5349-61. ©2016 AACR.
PMID: 27189164 [PubMed - in process]
Source: Clinical Cancer Research - October 31, 2016 Category: Cancer & Oncology Authors: Zhang H, Prado K, Zhang KX, Peek EM, Lee J, Wang X, Huang J, Li G, Pellegrini M, Chin AI Tags: Clin Cancer Res Source Type: research
Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors.
CONCLUSION: We developed a technically and biologically robust NanoString gene expression assay of MEK pathway output, compatible with the quantities of FFPET routinely available. The gene signatures identified a different patient population for MEK inhibitor treatment compared with KRAS mutation testing. The predictive power of the MEK signature should be studied further in clinical trials.
PMID: 27733477 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 11, 2016 Category: Cancer & Oncology Authors: Brant RG, Sharpe A, Liptrot T, Dry J, Harrington EA, Barrett JC, Whalley N, Womack C, Smith PD, Hodgson D Tags: Clin Cancer Res Source Type: research
A novel compound ARN-3236 inhibits Salt Inducible Kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel.
CONCLUSIONS: ARN-3236 is the first orally available inhibitor of SIK2 to be evaluated against ovarian cancer in preclinical models and shows promise in inhibiting ovarian cancer growth and enhancing paclitaxel chemosensitivity.
PMID: 27678456 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - September 26, 2016 Category: Cancer & Oncology Authors: Zhou J, Alfraidi A, Zhang S, Santiago-O'Farrill J, Yerramreddy V, Alsaadid A, Ahmed AA, Yang H, Liu J, Mao W, Takemori H, Wang Y, Vankayalapati H, Lu Z, Bast RC Tags: Clin Cancer Res Source Type: research
